ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML treatment was revolutionized by the use of the BCR-ABL TKI imatinib (formerly STI571, Gleevec®), a compound that was writing the first success stories in the field of targeted neoplastic treatment [43].